Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,623 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: normal saline solution placebo Clear all

Conditions: HIV Infections
Interventions: VRC01, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 13
States / cities: San Diego, California • Aurora, Colorado • Chicago, Illinois + 10 more

Conditions: Surgery-Complications, Respiratory Complication, Lung Injury, Acute
Interventions: Dexmedetomidine Hydrochloride, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cytomegalovirus Infections
Interventions: CMV gB vaccine, MF59 adjuvant, Placebo; Biological · Drug
Lead sponsor: Robert Pass, MD; Other
Eligibility: 14 Years to 40 Years · Female only
Enrollment: 464 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2010
U.S. locations: 2
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama

Conditions: Crohn Colitis
Interventions: Remestemcel-L, Placebo; Drug · Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Clostridia Difficile Colitis, Clostridium; Sepsis
Interventions: Bezlotoxumab, Normal Saline; Biological · Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Postdural Puncture Headache, Sphenopalatine Ganglion Block
Interventions: bupivacaine, placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 45 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Diabetes Mellitus
Interventions: HM11260C, Placebo, Victoza; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: California City, California

Conditions: Smallpox
Interventions: Live vaccinia virus vaccine, MVA Smallpox Vaccine, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 38 Years
Enrollment: 226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 7
States / cities: Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 4 more

Conditions: Healthy Volunteers
Interventions: NasoShield, Placebo; Biological · Other
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Obstructive Sleep Apnea
Interventions: Dexmedetomidine, Placebo; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Supracondylar Humerus Fracture, Infection
Interventions: Cefazolin, normal saline; Drug
Lead sponsor: Legacy Health System; Other
Eligibility: 0 Years to 18 Years
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Pelvic Organ Prolapse, PONV
Interventions: Dexamethasone, Placebo; Drug
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years to 81 Years · Female only
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Spinal Cord Injuries, Type 2 Diabetes
Interventions: Semaglutide Injectable Product, Placebo; Drug · Other
Lead sponsor: Marzieh Salehi; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Diffuse Cutaneous Systemic Sclerosis, Scleroderma, dcSSc
Interventions: Brentuximab Vedotin, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 8
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 5 more

Conditions: Sedation, Respiration, Artificial, Length of Stay
Interventions: Dexmedetomidine, Normal Saline; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: COPD
Interventions: OnabotulinumtoxinA, Placebo; Drug · Other
Lead sponsor: RMW Testing; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Webster, Texas

Conditions: Osteoporosis
Interventions: Zoledronic Acid, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 68 Years to 90 Years · Female only
Enrollment: 2,456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 30
States / cities: Tucson, Arizona • Little Rock, Arkansas • Beverly Hills, California + 26 more

Conditions: COVID-19
Interventions: SARS-CoV-2 mRNA vaccine formulation 1, SARS-CoV-2 mRNA vaccine formulation 2, SARS-CoV-2 mRNA vaccine formulation 3, Placebo (0.9% normal saline); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 12
States / cities: Rolling Hills Estates, California • Hollywood, Florida • Miami, Florida + 9 more

Conditions: Congestive Heart Failure
Interventions: Albuterol, Normal Saline; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Osteoarthritis of Knee
Interventions: Cryopreserved Devitalized Adipose Tissue Allograft, Normal Saline (Placebo); Biological · Other
Lead sponsor: Britecyte; Network
Eligibility: 18 Years to 80 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 7
States / cities: Baltimore, Maryland • Hagerstown, Maryland • Oxon Hill, Maryland + 4 more

Conditions: Stiff-Person Syndrome
Interventions: Intravenous Immunoglobulins, Human, Placebos; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy
Interventions: Gadopentetate dimeglumine (Magnevist, BAY86-4882), Moxifloxacin (BAY12-8039), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Asthma
Interventions: GSK3772847, Placebo, Fluticasone propionate/salmeterol, Fluticasone propionate; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 33
States / cities: Birmingham, Alabama • Scottsboro, Alabama • Bakersfield, California + 24 more

Conditions: Influenza, Human, SARS-CoV-2 Infection, COVID-19
Interventions: BNT162b2 (Omi XBB.1.5)/RIV, BNT162b2 (Omi XBB.1.5), RIV, Normal saline placebo; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 644 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 30
States / cities: Lake Forest, California • Tustin, California • Walnut Creek, California + 22 more

Search by objective public record fields.

Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART)

Dexmedetomidine Infusion and Postoperative Lung Aeration After Thoracic Surgery

Recombinant CMV gB Vaccine in Postpartum Women

Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis

Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery.

Sphenopalatine Ganglion Block for Post-Dural Puncture Headache

A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

MVA Post-Event: Administration Timing and Boost Study

NasoShield in Healthy Adults to Study Safety and Immunogenicity

Dex as Analgesic Adjuvant in OSA Patients

Supracondylar Pinning Antibiotic Stewardship (SPAS) Trial

Effects of Preoperative Dexamethasone Study on QOL After Vaginal Reconstructive Surgery for POP

Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes

Brentuximab Vedotin for Systemic Sclerosis

Dexmedetomidine for Postoperative Sedation in Patients Undergoing Repair of Thoracoabdominal Aortic Aneurysms

A Study to Evaluate Safety and Efficacy of BOTOX in Adults With Moderate COPD

Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)

Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older

Nebulized Albuterol for Congestive Heart Failure Exacerbation

A Phase 1/2a to Evaluate the Safety and Efficacy of Adipose Tissue Allograft (BRC-OA) in Patients With Osteoarthritis of the Knee

Randomized Placebo Controlled Trial of IVIg in Glycine Receptor Antibody Positive Stiff-person Syndrome

Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects

Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma

A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults